title: Salicylate decreases production of AmpC type beta-lactamases and increases susceptibility to beta-lactams in a Morganella morganii clinical isolate.
abstract: The effect of salicylate, a marRAB inducer, on the resistance to beta-lactams was characterized in an AmpC beta-lactamase hyperproducer Morganella morganii clinical isolate (the M1 strain). Results were compared with those of the effect of salicylate in a wild-type M. morganii strain. Salicylate induced a decreased susceptibility to nalidixic acid, norfloxacin and tetracycline and simultaneously increased the susceptibility to beta-lactams apparently due to the repression of AmpC beta-lactamase synthesis in the M1 strain. Likewise, salicylate only repressed 46 kDa outer membrane protein expression in the wild-type strain, since the clinical isolate M1 did not express it.
authors.affiliation: Microbiology, Department of Clinical Sciences II, Health Sciences Building, University of Las Palmas de G.C., Dr. Pasteur, 35080- Las Palmas de, G.C. Spain. 928253005@infonegocio.com
authors.forename: María M
authors.initials: MM
authors.lastname: Tavío
authors.forename: Mariagrazia
authors.initials: M
authors.lastname: Perilli
authors.forename: Jordi
authors.initials: J
authors.lastname: Vila
authors.forename: Pino
authors.initials: P
authors.lastname: Becerro
authors.forename: Lucía
authors.initials: L
authors.lastname: Casañas
authors.forename: Gianfranco
authors.initials: G
authors.lastname: Amicosante
authors.forename: María Teresa
authors.initials: MT
authors.lastname: Jiménez de Anta
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology; D001425:Bacterial Outer Membrane Proteins / Q000032:analysis / Q000096:biosynthesis; D001426:Bacterial Proteins / Q000096:biosynthesis*; D024901:Drug Resistance, Multiple, Bacterial / Q000187:drug effects / Q000235:genetics; D015964:Gene Expression Regulation, Bacterial / Q000187:drug effects*; D006801:Humans; D007297:Inpatients; D008826:Microbial Sensitivity Tests; D020613:Morganella morganii / Q000187:drug effects* / Q000201:enzymology* / Q000302:isolation & purification; D009268:Nalidixic Acid / Q000494:pharmacology; D009643:Norfloxacin / Q000494:pharmacology; D012459:Salicylates / Q000494:pharmacology*; D013752:Tetracycline / Q000494:pharmacology; D014556:Urine / Q000382:microbiology; D018440:beta-Lactam Resistance / Q000187:drug effects; D001618:beta-Lactamases / Q000096:biosynthesis*; D047090:beta-Lactams / Q000494:pharmacology
chemical_list: D000900:Anti-Bacterial Agents; D001425:Bacterial Outer Membrane Proteins; D001426:Bacterial Proteins; D012459:Salicylates; D047090:beta-Lactams; D009268:Nalidixic Acid; C048795:AmpC beta-lactamases; D001618:beta-Lactamases; D013752:Tetracycline; D009643:Norfloxacin